← Ablatotech Signals
Immunology SignalsArticle

A putative therapeutic target in inflammatory bowel disease: Q9HC29

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
July 7, 2026 · Lead editor: ImmunologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — Q9HC29 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in inflammatory bowel disease.

# Signals Article on Putative Target Q9HC29 for Inflammatory Bowel Disease

Background

The protein encoded by the putative target Q9HC29 has emerged as a candidate of interest in the context of inflammatory bowel disease (IBD). Preliminary data suggest that this protein may play a role in the inflammatory processes associated with IBD, warranting further investigation into its therapeutic potential. Given the complex nature of IBD, characterized by chronic inflammation of the gastrointestinal tract, understanding the molecular underpinnings of this disease is crucial for developing novel treatment strategies.

Data-mining rationale

Our analysis utilized the GeoMicroarrayReanalysis approach, cross-referencing reviewed human entries in the UniProt database for "inflammatory bowel disease" against 340 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate UniProt:Q9HC29 was identified as being present in several expression-profiling studies, yet notably lacks any registered Phase 1 or higher clinical programs. This observation raises questions about its potential role in IBD and underscores the need for further exploration.

Why prior analyses may have missed this

Many of the GEO datasets analyzed predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which provides robust multiple-testing correction. As a result, previous analyses may not have accurately captured the expression dynamics of Q9HC29 in the context of IBD. The lack of rigorous statistical validation could explain why this candidate has not been prioritized in the search for therapeutic targets in IBD.

Reasoning for further validation

To substantiate the potential role of Q9HC29 in IBD, several experimental approaches are warranted: 1. Re-analyze the matched GEO datasets using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with greater confidence. 2. Validate the top differentially expressed genes, including Q9HC29, by quantitative PCR (qPCR) in an independent cohort of IBD patients to confirm expression patterns. 3. Investigate the tissue specificity of Q9HC29 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in gastrointestinal tissues. 4. Utilize pathway analysis tools like STRING and OmniPath to contextualize Q9HC29 within known biological pathways related to inflammation and IBD. 5. If validation is achieved, assess the druggability of Q9HC29 through databases such as DGIdb and ChEMBL to explore potential therapeutic interventions.

References

  • [UniProt: Q9HC29](https://www.uniprot.org/uniprot/Q9HC29)
  • [NCBI GEO Accession GDS:200300955](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200300955)
  • [NCBI GEO Accession GDS:200151911](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200151911)
  • [NCBI GEO Accession GDS:200298981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200298981)
  • [NCBI GEO Accession GDS:200315114](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200315114)
  • [NCBI GEO Accession GDS:200310603](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200310603)

References

  1. UniProtKB. Entry Q9HC29. The UniProt Consortium. [link]
  2. UniProtKB. Entry Q9NSC7. The UniProt Consortium. [link]
  3. UniProtKB. Entry Q9NRD8. The UniProt Consortium. [link]
  4. UniProtKB. Entry P26927. The UniProt Consortium. [link]
  5. UniProtKB. Entry Q9Y5S8. The UniProt Consortium. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications